Navigation Links
New therapy for HIV/AIDS eliminates needles and excessive toxicity

A team led by Johns Hopkins scientists has found the first clear evidence that the process behind the human immune system's remarkable ability to recognize and respond to a million different proteins might have originated from a family of genes whose only apparent function is to jump around in genetic material. "Jumping genes" essentially cut themselves out of the genetic material, and scientists have suspected that this ability might have been borrowed by cells needing to build many different proteins from a specific, single set of instructions -- the key to recognizing a million immune-stimulating proteins. But until now, no jumping gene was known to behave just right.

Writing in the Dec. 23 issue of Nature, the researchers show that a jumping gene called Hermes, still active in the common house fly, creates changes in DNA very much like those created by the process behind antigen recognition. "Hermes behaves more like the process used by the immune system to recognize a million different proteins, called antigens, than any previously studied jumping gene," says Nancy Craig, Ph.D., professor of molecular biology and genetics in Johns Hopkins' Institute for Basic Biomedical Sciences and a Howard Hughes Medical Institute investigator. "It provides the first real evidence that the genetic processes behind antigen diversity might have evolved from the activity of a jumping gene, likely a close relative of Hermes." Recognition of so many antigens allows the immune system to fight infection and distinguish friend from foe. The "big picture" behind this ability is that cells build proteins called antibodies that bind to particular antigens, but the early steps of that process have been difficult to study. Hermes should help reveal some secrets of this process, the researchers say. "The immune system takes an approach to protein building similar to that of diners creating a meal at a cafeteria, but how the immun
'"/>

Source:


Page: 1 2 3

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
9. Gene therapy for Parkinsons disease moves forward in animals
10. Pulsating ultrasound enhances gene therapy for tumors
11. Antiretroviral therapy may prevent excess risk of some cancers in people with HIV

Post Your Comments:
(Date:11/9/2009)...ADELPHIA, NOVEMBER 9, 2009 A nutritionist whose ...etables to the federal Women, Infants and Children...s Agnes Higgins Award for outstanding achievement ...il Harrison, Ph.D., MNS, , a professor in the Depa...ity of California, Los Angeles School of Public He...
(Date:11/8/2009)...HEALTH EDUCATION DESIGNED FOR ADULTS WITH INTELLEC...VES , An Indiana University study involving adu...adults increased their personal health knowledge a..., Adults with ID, an internationally accepted ter...es of obesity, physical inactivity and preventable...
(Date:11/6/2009)...-dwelling ants generally live in harmony with thei...hen they run out of space in their trees of choice...s. , The research, published in the November iss...ocument that ants bore into live trees, and it reo...tween ants and plants. , Ants and certain specie...
Breaking Biology News(10 mins):March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 2Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 3Ants are friendly to some trees, but not others 2Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal 28R 29 Solution and Announcement of Lawsuit by Sepracor UCB 49926 1Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal 28R 29 Solution and Announcement of Lawsuit by Sepracor UCB 49926 2Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal 28R 29 Solution and Announcement of Lawsuit by Sepracor UCB 49926 3Conceive Introduces New MyConceive Online Community for Women Seeking to Get Pregnant 49921 1Conceive Introduces New MyConceive Online Community for Women Seeking to Get Pregnant 49921 2Preclinical Proof of Concept Studies Published for Novavax Seasonal Influenza Virus Like Particle Vaccine 12765 1Preclinical Proof of Concept Studies Published for Novavax Seasonal Influenza Virus Like Particle Vaccine 12765 2Preclinical Proof of Concept Studies Published for Novavax Seasonal Influenza Virus Like Particle Vaccine 12765 3Preclinical Proof of Concept Studies Published for Novavax Seasonal Influenza Virus Like Particle Vaccine 12765 4
... in German . , DNA, the molecule that acts as ... life, is highly resistant against alteration by u...for its photostability presents some puzzling prob...four chemical bases that make up the DNA molecule....showing that DNA strands differ in their light sen...
...tion to the IOF World Congress on Osteoporosis 200...until October 31, 2008. , To benefit from lower ...www.iofbonehealth.org/wco/2008/homepage.html . Sp...ants from non-OECD countries and for IOF members. ...at higher rates, will be possible. , Your chance...
..., Inc. (Nasdaq:,AWRE), a leading supplier of broad...led a conference call to discuss the company,s ope...ursday, October 23, 2008, at 5:00 p.m.,Eastern Tim...st the,earnings conference call., This call is be...Investor Relations page of our website at http://...
Other Biology News:Can genetic information be controlled by light? 2Aware Announces Q3 2008 Earnings Conference Call 2
(Date:11/8/2009)...ovember 6, 2009 As global temperatures and energy...gy will be key to a sustainable future. An attra...two studies published online in Genome Research ...enome structures of bioethanol-producing microorga...cal in developing new technologies needed to imple...
(Date:11/6/2009)..., LYNBROOK, N.Y., Nov. 6 /PRNewswire-FirstCall/ -..., a biopharmaceutical company developing first-in-...its financial results for the third quarter ended ...y that, in September of this year, the FDA,s Arthr...y a vote of 12-0, the approval of XIAFLEX(TM) for ...
(Date:11/6/2009)..., SAN MATEO, Calif., Nov. 6 /PRNewswire-FirstCall...Completed transfer of Qutenza(TM) E.U. Marketing A... significant progress in commercial readiness acti...es; Senior Director, Marketing; and Director, Comm...o board as director and Audit Committee chairman ...
(Date:11/6/2009)... The agenda for Arrowhead&rs...erence, which is set to take place on February 22-...his three day conference we will highlight key iss...eakers to share their experiences. , ...09 -- The agenda for Arrowhead’s 2010 Perso...
Breaking Biology Technology:Genomes of biofuel yeasts reveal clues that could boost fuel ethanol production worldwide 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3
...XEL International Corporation (Nasdaq: PRXL ), a...r, will address important industry issues at the D...Meeting, being held from March 23 - 25, 2009 in Be...rs will present on topics ranging from global bios...mbination products, and clinical process validatio...
...stCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:...results for the fourth quarter and year ended Dece...les results in our Medical Products Business and w... new technology initiatives despite a challenging ...t and CEO of Angiotech. "Not only did we increase ...
...nd AMSTERDAM, March 5 ,Agendia, a world leader in ...appointment of Dr. Albert A. (Al) Luderer to its S...30 years of experience in in vitro medical,diagnos...ent. Currently, he,is the Chief Executive Officer ...y using innovative platform technologies to dramat...
Other Biology Technology:PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 2PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 3PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 4PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 5Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 2Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 4Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 5Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 6Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 7Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 8Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 9Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 10Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 11Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 12Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 13Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 14Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 15Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 16Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 17Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 18Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 19Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 20Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 21Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 22Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 23Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 24Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 25Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 26Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 27Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 28Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board 2
AC1 Auto System, BioChemi™ Camera from UVP
Rabbit Anti-Pendrin (H-195) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
GeneAmp AccuRT RNA PCR Kit with Controls from Applied Biosystems
Mouse Anti-Human HLA-DRbeta Monoclonal Antibody, Unconjugated, Clone DA2 from Santa Cruz Biotechnology, Inc.
Biology Products: